Open an account

Hoth Therapeutics

RKTO · NASDAQ

$0.5311+$0.0341 (+6.86%)TodayMarket closed ·
Prev close $0.497

About RKTO

The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15.

Employees
2
Headquarters
New York City, New York
Listed
Feb 15, 2019
Sector
Health Care
Industry
Pharmaceuticals
Website
hoththerapeutics.com

RKTO key statistics

Market cap
13.22M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
347.00K
Volume
942.23K
Open price
$0.5384
High today
$0.5798
Low today
$0.53
52 Week high
$2.45
52 Week low
$0.4829

Hoth Therapeutics (RKTO) at a glance

As of Oct 20, 2026, Hoth Therapeutics (RKTO) shares are priced at $0.5311, giving the company a market cap of 13.22M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.53 and $0.5798. The current price is 0.2% above the day's low and 8.4% below its high.

Volume so far is 942.23K shares, above the average of 347.00K shares a day.

Over the past year Hoth Therapeutics has ranged from $0.4829 to $2.45, and now sits 2% of the way up that range.

Hoth Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q4 FY25 it reported -$0.16 per share against an estimate of -$0.102.

RKTO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 23.7% on average.

  1. Q1 FY24: reported -$0.46 per share against an estimate of -$0.4386
  2. Q2 FY24: reported -$0.24 per share against an estimate of -$0.4386
  3. Q3 FY24: reported -$0.31 per share against an estimate of -$0.3468
  4. Q4 FY24: reported -$0.32 per share against an estimate of -$0.3774
  5. Q1 FY25: reported -$0.27 per share against an estimate of -$0.2652
  6. Q2 FY25: reported -$0.17 per share against an estimate of -$0.1428
  7. Q3 FY25: reported -$0.30 per share against an estimate of -$0.102
  8. Q4 FY25: reported -$0.16 per share against an estimate of -$0.102

RKTO news

  • Press releasePRNewswire

    Rocket One Signs Agreement to Advance Nanomagnetic AI Chip Technology and Device Prototyping

  • Press releasePRNewswire

    Rocket One Signs Patent License Agreement with U.S. Air Force for Technology Designed to Capture and Neutralize Hostile Drones

  • Press releasePRNewswire

    Rocket One Signs Definitive Agreement to Acquire Revenue-Generating Tracer Drone Technologies, Accelerating AI and Counter-UAS Expansion Across Public Safety and Defense Markets

  • Press releasePRNewswire

    Rocket One Inc. to Attend IDGA's Counter UAS Summit August 25 - 26, 2026

  • Press releasePRNewswire

    Rocket One Launches Swarm Stage AI Drone-Swarm Threat Emulation Platform for U.S. Military Counter-UAS

  • Press releasePRNewswire

    Rocket One Accepted into Seagate Partner Program, Expanding AI Infrastructure and Enterprise Data Storage Ecosystem

  • Press releasePRNewswire

    Rocket One and NASA Reach Agreement to Advance Space AI Technology

  • Press releasePRNewswire

    Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing

Similar companies

Companies in the same industry as Hoth Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.